课题基金 / 基金详情

PHASE III SAFETY AND EFFICACY EVALUATION OF BETASERON IN MULTIPLE SCLEROSIS

PHASE III SAFETY AND EFFICACY EVALUATION OF BETASERON IN MULTIPLE SCLEROSIS
倍他龙治疗多发性硬化症的 III 期安全性和疗效评价
批准号：
6247154
负责人：
TIMOTHY VOLIMER
金额：
$2.68万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-04-01 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6247154
关键词：
clinical research disease /disorder prevention /control drug screening /evaluation human subject human therapy evaluation immunotherapy interferon beta magnetic resonance imaging multiple sclerosis nervous system disorder chemotherapy outcomes research pathologic process

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study is to determine if the administration of Betaseron (interferon beta 1b) slows the progression of secondary- progressive multiple sclerosis. Betaseron has been approved by the FDA for use in MS patients with relapsing-remitting multiple sclerosis. It is the intent of this study to provide data which may support broadening the FDA indication for Betaseron in MS to include patients with secondary progressive MS. Outpatient "A" visits are followup with no use of GCRC resources.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文